Cambium Bio Ltd

Cambium Bio Ltd

AASX:CMB
0.45
AUD
0.00
(0.00%)
-0.17EPS
11.75MMarket Cap
Mar 04Next Earn

Total Valuation

AUD

As of June 30, 2026, Cambium Bio Ltd carries a market capitalization of 11.75M, placing it among publicly traded companies globally. Its enterprise value stands at 10.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.75M
Enterprise Value10.79M

Important Dates

Cambium Bio Ltd's next confirmed earnings release is scheduled for March 4, 2027.

Earnings Date3/4/2027

Share Statistics

As of June 30, 2026, Cambium Bio Ltd has 27.33M shares outstanding.

Shares Outstanding27.33M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio4.94
P/TBV Ratio-166.86

Financial Position

As of June 30, 2026, Cambium Bio Ltd maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.30, indicating elevated leverage, while an interest coverage ratio of -349.91 demonstrates limited ability to service its debt obligations.

Current Ratio0.95
Quick Ratio0.93
Debt / Equity6.30
Debt / EBITDA-0.03
Interest Coverage-349.91

Financial Efficiency

Over the twelve months ended June 30, 2026, Cambium Bio Ltd posted a negative return on equity (ROE) of -194.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -116.06, reflecting losses generated across the asset base.

Return on Equity (ROE)-194.37
Return on Assets (ROA)-116.06

Stock Price Statistics

AUD

As of the close on October 21, 2026, Cambium Bio Ltd's stock has declined approximately 6.25% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.45.

52-Week Price Change-6.25%
50-Day Moving Average0.44
200-Day Moving Average0.45

Income Statement

AUD

These figures cover the twelve months ended June 30, 2026. EBITDA reached -4.81M, while operating income came in at -4.81M.

Operating Income-4.81M
Pretax Income-4.10M
Net Income-4.10M
EBITDA-4.81M
EBIT-4.81M
Earnings Per Share (EPS)-0.17

Balance Sheet

AUD

As of June 30, 2026, Cambium Bio Ltd holds 1.12M in cash and equivalents against 149,804.00 in total debt, resulting in a net debt position of -966,363.00. Total book value stands at 2.38M, with working capital of -72,986.00 providing operational flexibility.

Cash & Cash Equivalents1.12M
Total Debt149,804.00
Net Debt-966,363.00
Equity (Book Value)2.38M
Book Value Per Share0.09
Working Capital-72,986.00

Cash Flow

AUD

These figures cover the twelve months ended June 30, 2026.

Capital Expenditures-2,638.00

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -36.11, meaning Cambium Bio Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-36.11

Stock Splits

Cambium Bio Ltd's most recent stock split took place on July 17, 2024 with a 100:1 split ratio.

Last Split Date7/17/2024
Split Ratio100:1